Immunoprecise Antibodies Ltd (IPA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access IPA Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Immunoprecise Antibodies Ltd adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jan 31 2026)
(Oct 31 2025) (Jul 31 2025) (Apr 30 2025) (Jan 31 2025)
Assets
Cash & cash equivalent0.00
Cash, Cash Equivalents Other7.82
Current Tax Assets Current0.10
Cash & Short-term Investments7.00
Inventories1.52
Other Current Assets4.15
Total Current Assets13.58
Equipment/Property/Plant Net11.42
Goodwill net5.96
Intangible Assets0.77
Other Assets, Noncurrent0.45
Total Assets32.19
Liabilities
Current Accounts Payable AndAccrued Liabilities0.00
Other Liabilities, Current6.53
Total Current Liabilities6.53
Total Long-term Debt0.00
Deferred Tax Liabilities, Net LI0.18
Other liabilities, Noncurrent8.37
Total Liabilities15.08
Stockholders' Equity
Other Equity0.00
Common Stockholder's Equity17.11
Total Stockholder's Equity17.11
Liabilities & Stockholder's Equity32.19
4 historic quarters locked

Sign in to unlock the full Immunoprecise Antibodies Ltd balance sheet history.

About Mindwalk Holdings Corp Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-312694

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.